Hasan Çağrı Yıldırım

36PUBLICATIONS
199CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHost-parasite interactionsNutrigenomics and personalised nutrition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Jul 28, 2026
Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.

|Jun 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis.

|Feb 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Baris Koksal, Hasan Cagri Yildirim, Deniz Can Guven

|Oct 28, 2025
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Gokhan Sahin, Sercan Ön

|Oct 13, 2025
HERC2 as a Potential Biomarker for Prognosis and Response to Bevacizumab in Ovarian Cancer: A Bioinformatics Approach.

Fatih Yay, Hasan Çağrı Yıldırım

Pageof 6

Frequent Collaborators

12 joint publications

Deniz Can Guven

7 joint publications

Fatih Kus

5 joint publications

Nargiz Majidova

5 joint publications

Elif Sahin